Immunotherapy Drugs Market Growth Factors, Top Manufacturers

Pfizer is the second-leading player in the global immunotherapy drugs market. The company has a strong presence in more than 90 countries and sells its products in more than 125 countries. The company offers innovative drugs and biologics in the fields of cancer and inflammatory diseases. It mainly focuses on inorganic growth strategies such as collaborations, agreements, and acquisitions. In past years, the company has conducted joint ventures with GSK (UK), Mylan (US), and Bain Capital (US) to form three separate entities. These efforts are in line with its strategy to enhance its product portfolio and geographic presence. Moreover, Pfizer has demonstrated a significant focus on product innovation in the field of cytokine products.

Immunotherapy Drugs Market Overview:

The Global Immunotherapy Drugs Market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. The growth of this market is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, increasing adoption of immunotherapy drugs over conventional treatments, and a favorable approval scenario. However, timeline issues, side-effects, and manufacturing complexities and a high attrition rate in the product development cycle are expected to challenge market growth.

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755

Key Players:

The major players in the global immunotherapy drugs market are F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), Merck & Co (US), Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany), BioNTech SE, Genmab, Gilead Sciences, NBE Therapeutics, Teva Pharmaceuticals, Bayer, and Bristol-Myers Squibb.

Request For Sample:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=137717755

Segmentation:

By type, the monoclonal antibodies segment accounted for the largest market share in 2019.

On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs. The mAbs segment accounted for the largest share of the immunotherapy drugs market in 2019. The large share of this segment is mainly owing to their high specificity & few side-effects, increasing focus on personalized medicines, initiatives by industry players, and the increasing target disease incidence and patient pool.

Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.

Based on therapeutic area, the immunotherapy drugs market has been segmented into cancer, autoimmune and inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the immunotherapy drugs market in 2019. Factors such as the large number of approvals, rising prevalence of cancer, rising demand for monoclonal antibodies & personalized medicines, and the expansion of policies by payers to cover most immunotherapy drugs are driving the market growth.

By end user, hospitals to witness the highest growth during the forecast period
On the basis of end users, the global immunotherapy drugs market is broadly segmented into hospitals, clinics, and other end users. Hospitals accounted for the largest share of the global market in 2019. This segment is also estimated to grow at the highest CAGR of 12.1% over the forecast period. The large share of this segment can be attributed to the rising spending by hospitals for immunotherapies and the demand for advanced treatments currently only provided by hospitals.

Get Detailed Information:

https://www.marketsandmarkets.com/Market-Reports/immunotherapy-drug-market-137717755.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model — GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1–888–600–6441
sales@marketsandmarkets.com